• You-Wun Jheng, Ya-Ning Chan, Chih-Jung Wu, Ming-Wei Lin, Ling-Ming Tseng, and Ya-Jung Wang.
• From the Department of Nursing, Taichung Veterans General Hospital Taichung, Taiwan.
• Pain Manag Nurs. 2024 Jun 1; 25 (3): 308315308-315.

BackgroundDespite the significant impact of chemotherapy-induced peripheral neuropathy on the quality of life for breast cancer survivors, there is a notable lack of comprehensive research. Therefore, a crucial need exists for further systematic investigation and inquiry into this matter.AimsThis study examined predictors of quality of life in breast cancer survivors with chemotherapy-induced peripheral neuropathy.DesignA cross-sectional, correlational design.SettingsThis study was conducted at a medical center in northern Taiwan and a teaching hospital in northeastern Taiwan.Participants/SubjectsOne hundred and thirty adult women with breast cancer, who have undergone chemotherapy and obtained a Total Neuropathy Scale-Clinical Version score>0, were enrolled.MethodsNeuropathic pain, sleep disturbances, depression, and quality of life were evaluated using multiple regression analysis to identify quality of life predictors. Clinical importance was established using the minimally important difference of Functional Assessment of Cancer Therapy-Breast.ResultsThe study indicated that improving depression (B = -10.87, p < .001) and neuropathic pain (B = -8.33, p = .004) may enhance the quality of life of breast cancer survivors with chemotherapy-induced peripheral neuropathy. Moreover, the individual's marital status and family history of breast cancer were identified as predictive factors.ConclusionsThis study illuminates quality of life determinants for breast cancer survivors with chemotherapy-induced peripheral neuropathy, advocating comprehensive care and addressing depression and neuropathic pain for better outcomes.Copyright © 2024 American Society for Pain Management Nursing. Published by Elsevier Inc. All rights reserved.

38 keywords...

hide…